COVID-19 mRNA vaccine booster in patients with autoimmune rheumatic diseases

Rheumatology (Oxford). 2022 Nov 2;61(11):e328-e330. doi: 10.1093/rheumatology/keac296.

Authors

Chiara Cardelli^{1

2}, Teresita Caruso^{1

3}, Chiara Tani², Federico Pratesi^{1

4}, Rosaria Talarico², Federica Di Cianni^{1

2}, Nazzareno Italiano^{1

2}, Elenia Laurino^{1

2}, Michele Moretti^{1

2}, Giancarlo Cascarano^{1

2}, Michele Diomedi^{1

2}, Luca Gualtieri^{1

2}, Rossella D'Urzo², Paola Migliorini^{1

3}, Marta Mosca^{1

2}

Affiliations

¹ Department of Clinical and Experimental Medicine, University of Pisa.
² Rheumatology Unit.
³ Immunoallergology Unit, Azienda Ospedaliero-Universitaria Pisana.
⁴ Department of Translational Research and NTMS, University of Pisa, Pisa, Italy.

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Autoimmune Diseases*
COVID-19 Vaccines
COVID-19*
Humans
Rheumatic Diseases*
mRNA Vaccines

Substances

COVID-19 Vaccines